Paper 70 - PHASE 2 STUDY TO EVALUATE PALBOCICLIB (IBRANCE®) IN COMBINATION WITH IRINOTECAN AND TEMOZOLOMIDE IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY EWING SARCOMA

Author(s)

• 

  Theodore W. Laetsch, MD (he/him/his)

  Associate Professor
  The Children’s Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA, USA
  Philadelphia, Pennsylvania, United States

  Slides

Co-Author(s)

• MT

  Mustafa Tezer Kutluk, MD, PhD

  Hacettepe University Faculty of Medicine & Cancer Institute
  Ankara, Ankara, Turkey
• SR

  Sameer Rastogi, MD

  All India Institute of Medical Sciences
  New Delhi, Delhi, India
• HJ

  Hyoung Jin Kang, MD, PhD

  Seoul National University College of Medicine, Seoul National University Cancer Research Institute
  Seoul, Chagang-do, North Korea
• DM

  Daniel Morgenstern, MD

  The Hospital for Sick Children and University of Toronto
  Toronto, Ontario, Canada
• 

  Katarzyna Alicja Juszczak-Kosela, MD (she/her/hers)

  Clinician
  Pfizer Inc
  Warsaw, Mazowieckie, Poland
• JM

  Jodi A. Muscal, MD

  Pfizer Inc
  New York, New York, United States
• ZZ

  Zhe Zhang, MS

  Pfizer Inc
  San Diego, California, United States
• AH

  Ariadna Holynskyj, MD

  Pfizer Inc.
  New York, New York, United States
• NA

  Neslihan Aslan, MD

  Pfizer Inc
  Istanbul, Istanbul, Turkey
• BW

  Brenda J. Weigel, MD

  University of Minnesota, Minneapolis
  Minneapolis, Minnesota, United States
• KJ

  Katherine A. Janeway, MD MMSc

  Senior Physician
  Department of Pediatrics, Dana-Farber / Boston Children’s Cancer and Blood Disorders Center Harvard Medical School
  Boston, Massachusetts, United States
• DH

  Douglas S. Hawkins, MD

  Seattle Children’s Hospital, University of Washington
  Seattle, Washington, United States
• AC

  Anderson B. Collier, III, MD

  Nemours Children’s Health
  Jacksonville, Florida, United States